Over 12 million people in the United States died from all causes between the beginning of January 2020 and August 21, 2023. Over 1.1 million of those deaths were with confirmed or presumed COVID-19.
Vaccine rollout in the United States Finding a safe and effective COVID-19 vaccine was an urgent health priority since the very start of the pandemic. In the United States, the first two vaccines were authorized and recommended for use in December 2020. One has been developed by Massachusetts-based biotech company Moderna, and the number of Moderna COVID-19 vaccines administered in the U.S. was over 250 million. Moderna has also said that its vaccine is effective against the coronavirus variants first identified in the UK and South Africa.
Official statistics are produced impartially and free from political influence.
Official statistics are produced impartially and free from political influence.
Deaths counts for influenza, pneumonia, and COVID-19 reported to NCHS by week ending date, by state and HHS region, and age group.
Between January and August 2020, there has been approximately 48.2 thousand deaths in England and Wales with COVID-19 as an underlying cause. As illustrated in the table, the number of deaths as a result of COVID-19 are much higher than from either pneumonia or influenza. There has been over three times the number of deaths from COVID-19 than pneumonia and influenza so far in 2020. The overall number of confirmed COVID-19 cases in the UK can be found here. For further information about the coronavirus (COVID-19) pandemic, please visit our dedicated Facts and Figures page.
This file contains the provisional percent of total deaths by week for COVID-19, Influenza, and Respiratory Syncytial Virus for deaths occurring among residents in the United States. Provisional data are based on non-final counts of deaths based on the flow of mortality data in National Vital Statistics System.
As of January 6, 2022, an average of 1,192 people per day have died from COVID-19 in the U.S. since the first case was confirmed in the country on January 20th the year before. On an average day, nearly 8,000 people die from all causes in the United States, based on data from 2019. Based on the latest information, roughly one in seven deaths each day were related to COVID-19 between January 2020 and January 2022. However, there were even days when more than every second death in the U.S. was connected to COVID-19. The daily death toll from the seasonal flu, using preliminary maximum estimates from the 2019-2020 influenza season, stood at an average of around 332 people. We have to keep in mind that a comparison of influenza and COVID-19 is somewhat difficult. COVID-19 cases and deaths are counted continuously since the begin of the pandemic, whereas flue counts are seasonal and often less accurate. Furthermore, during the last two years, COVID-19 more or less 'replaced' the flu, with COVID-19 absorbing potential flu cases. Many countries reported a very weak seasonal flu activity during the COVID-19 pandemic. But it has yet to be seen how the two infectious diseases will develop side by side during the winter season 2021/2022 and in the years to come.
Symptoms and self-isolation COVID-19 and influenza share similar symptoms – a cough, runny nose, and tiredness – and telling the difference between the two can be difficult. If you have minor symptoms, there is no need to seek urgent medical care, but it is recommended that you self-isolate, whereas rules vary from country to country. Additionally, rules depend on someone's vaccination status and infection history. However, if you think you have the disease, a diagnostic test can show if you have an active infection.
Scientists alert to coronavirus mutations The genetic material of the novel coronavirus is RNA, not DNA. Other notable human diseases caused by RNA viruses include SARS, Ebola, and influenza. A continual problem that vaccine developers encounter is that viruses can mutate, and a treatment developed against a certain virus type may not work on a mutated form. The seasonal flu vaccine, for example, is different each year because influenza viruses are frequently mutating, and it is critical that those genetic changes continue to be tracked.
These reports summarise the surveillance of influenza, COVID-19 and other seasonal respiratory illnesses in England.
Weekly findings from community, primary care, secondary care and mortality surveillance systems are included in the reports.
This page includes reports published from 20 July 2023 to the present.
Please note that after the week 21 report (covering data up to week 20), this surveillance report will move to a condensed summer report and released every two weeks.
Previous reports on influenza surveillance are also available for:
View previous COVID-19 surveillance reports.
View the pre-release access list for these reports.
Our statistical practice is regulated by the Office for Statistics Regulation (OSR). The OSR sets the standards of trustworthiness, quality and value in the https://code.statisticsauthority.gov.uk/" class="govuk-link">Code of Practice for Statistics that all producers of Official Statistics should adhere to.
Open Government Licence 3.0http://www.nationalarchives.gov.uk/doc/open-government-licence/version/3/
License information was derived automatically
Provisional counts of the number of death occurrences in England and Wales due to coronavirus (COVID-19) and influenza and pneumonia, by age, sex and place of death.
These reports summarise the surveillance of influenza, COVID-19 and other seasonal respiratory illnesses.
Weekly findings from community, primary care, secondary care and mortality surveillance systems are included in the reports.
This page includes reports published from 14 July 2022 to 6 July 2023.
Previous reports on influenza surveillance are also available for:
View previous COVID-19 surveillance reports.
https://www.usa.gov/government-workshttps://www.usa.gov/government-works
This file contains the provisional percent of total deaths by week for COVID-19, Influenza, and Respiratory Syncytial Virus for deaths occurring among residents in the United States, by sex, age group, and race and Hispanic origin. Provisional data are based on non-final counts of deaths based on the flow of mortality data in National Vital Statistics System.
The burden of influenza in the United States can vary from year to year depending on which viruses are circulating, how many people receive an influenza vaccination, and how effective the vaccination is in that particular year. During the 2023-2024 flu season, around 28,000 people lost their lives to the disease. Although most people recover from influenza without needing medical care, the disease can be deadly among young children, the elderly, and those with weakened immune systems or chronic illnesses. Deaths due to influenza Even though most people recover from influenza without medical care, influenza and pneumonia can be deadly, especially for older people and those with certain preexisting conditions. Influenza is a common cause of pneumonia and although most cases of influenza do not develop into pneumonia, those that do are often more severe and more deadly. Deaths due to influenza are most common among the elderly, with a mortality rate of around 32 per 100,000 population during the 2023-2024 flu season. In comparison, the mortality rate for those aged 50 to 64 years was 9.1 per 100,000 population. Flu vaccinations The most effective way to prevent influenza is to receive an annual influenza vaccination. These vaccines have proven to be safe and are usually cheap and easily accessible. Nevertheless, every year a large share of the population in the United States still fails to get vaccinated against influenza. For example, in the 2022-2023 flu season, only 35 percent of those aged 18 to 49 years received a flu vaccination. Unsurprisingly, children and the elderly are the most likely to get vaccinated. It is estimated that during the 2022-2023 flu season, vaccinations prevented over 929 thousand influenza cases among children aged 6 months to 4 years.
Background: As of October 2020, COVID-19 has caused 1,000,000 deaths worldwide. However, large-scale studies of COVID-19 mortality and new-onset comorbidity compared to individuals tested negative for COVID-19 and individuals tested for influenza A/B are lacking. We investigated COVID-19 30-day mortality and new-onset comorbidity compared to individuals with negative COVID-19 test results and individuals tested for influenza A/B.Methods and findings: This population-based cohort study utilized electronic health records covering roughly half (n = 2,647,229) of Denmark's population, with nationwide linkage of microbiology test results and death records. All individuals ≥18 years tested for COVID-19 and individuals tested for influenza A/B were followed from 11/2017 to 06/2020. Main outcome was 30-day mortality after a test for either COVID-19 or influenza. Secondary outcomes were major comorbidity diagnoses 30-days after the test for either COVID-19 or influenza A/B. In total, 224,639 individuals were tested for COVID-19. To enhance comparability, we stratified the population for in- and outpatient status at the time of testing. Among inpatients positive for COVID-19, 356 of 1,657 (21%) died within 30 days, which was a 3.0 to 3.1-fold increased 30-day mortality rate, when compared to influenza and COVID-19-negative inpatients (all p < 0.001). For outpatients, 128 of 6,263 (2%) COVID-19-positive patients died within 30 days, which was a 5.5 to 6.9-fold increased mortality rate compared to individuals tested negative for COVID-19 or individuals tested positive or negative for influenza, respectively (all p < 0.001). Compared to hospitalized patients with influenza A/B, new-onset ischemic stroke, diabetes and nephropathy occurred more frequently in inpatients with COVID-19 (all p < 0.05).Conclusions: In this population-based study comparing COVID-19 positive with COVID-19 negative individuals and individuals tested for influenza, COVID-19 was associated with increased rates of major systemic and vascular comorbidity and substantially higher mortality. Results should be interpreted with caution because of differences in test strategies for COVID-19 and influenza, use of aggregated data, the limited 30-day follow-up and the possibility for changing mortality rates as the pandemic unfolds. However, the true COVID-19 mortality may even be higher than the stated 3.0 to 5.5-fold increase, owing to more extensive testing for COVID-19.
https://www.usa.gov/government-workshttps://www.usa.gov/government-works
Effective September 27, 2023, this dataset will be updated weekly on Thursdays.
Deaths involving COVID-19, pneumonia, and influenza reported to NCHS by week ending date and by state
Influenza, also called the flu, is one of the most infectious diseases worldwide. Its symptoms range from mild to severe, and include sore throat, cough, runny nose, fever, headache, and muscle pain, but can also cause severe illness and death among high-risk populations such as the elderly and children. During the 2023-2024 flu season, there were 40 million cases of influenza in the United States. Influenza deaths Although influenza does not require medical attention for most people, it can be deadly, and causes thousands of deaths every year. The impact of influenza varies from year to year. The number of influenza deaths during the 2023-2024 flu season was 27,965. The vast majority of deaths attributed to influenza during the 2023-2024 flu season occurred among those aged 65 years and older. Vaccination An annual influenza vaccination remains the most effective way of preventing influenza. During the 2022-2023 flu season, influenza vaccinations prevented an estimated 2,479 deaths among U.S. adults aged 65 years and older. Although, flu vaccinations are accessible and cheap, a large share of the United States population still fails to get vaccinated every year. In 2022-2023, only 35 percent of those aged 18 to 49 years received a flu vaccination, much lower compared to children and the elderly.
Note: On April 30, 2024, the Federal mandate for COVID-19 and influenza associated hospitalization data to be reported to CDC’s National Healthcare Safety Network (NHSN) expired. Hospitalization data beyond April 30, 2024, will not be updated on the Open Data Portal. Hospitalization and ICU admission data collected from summer 2020 to May 10, 2023, are sourced from the California Hospital Association (CHA) Survey. Data collected on or after May 11, 2023, are sourced from CDC's National Healthcare Safety Network (NHSN).
Data is from the California Department of Public Health (CDPH) Respiratory Virus State Dashboard at https://www.cdph.ca.gov/Programs/CID/DCDC/Pages/Respiratory-Viruses/RespiratoryDashboard.aspx.
Data are updated each Friday around 2 pm.
For COVID-19 death data: As of January 1, 2023, data was sourced from the California Department of Public Health, California Comprehensive Death File (Dynamic), 2023–Present. Prior to January 1, 2023, death data was sourced from the COVID-19 case registry. The change in data source occurred in July 2023 and was applied retroactively to all 2023 data to provide a consistent source of death data for the year of 2023. Influenza death data was sourced from the California Department of Public Health, California Comprehensive Death File (Dynamic), 2020–Present.
COVID-19 testing data represent data received by CDPH through electronic laboratory reporting of test results for COVID-19 among residents of California. Testing date is the date the test was administered, and tests have a 1-day lag (except for the Los Angeles County, which has an additional 7-day lag). Influenza testing data represent data received by CDPH from clinical sentinel laboratories in California. These laboratories report the aggregate number of laboratory-confirmed influenza virus detections and total tests performed on a weekly basis. These data do not represent all influenza testing occurring in California and are available only at the state level.
https://www.usa.gov/government-works/https://www.usa.gov/government-works/
Corona virus cases in the US is stacking up higher and higher. Understanding this virus is crucial to stopping it's spread.
The dataset shows, deaths involving coronavirus disease 2019 (COVID-19), pneumonia, and influenza reported to NCHS by sex and age group and state.
Credits to this data set comes from : https://data.cdc.gov/NCHS/Provisional-COVID-19-Death-Counts-by-Sex-Age-and-S/9bhg-hcku
As of May 2, 2023, the outbreak of the coronavirus disease (COVID-19) had spread to almost every country in the world, and more than 6.86 million people had died after contracting the respiratory virus. Over 1.16 million of these deaths occurred in the United States.
Waves of infections Almost every country and territory worldwide have been affected by the COVID-19 disease. At the end of 2021 the virus was once again circulating at very high rates, even in countries with relatively high vaccination rates such as the United States and Germany. As rates of new infections increased, some countries in Europe, like Germany and Austria, tightened restrictions once again, specifically targeting those who were not yet vaccinated. However, by spring 2022, rates of new infections had decreased in many countries and restrictions were once again lifted.
What are the symptoms of the virus? It can take up to 14 days for symptoms of the illness to start being noticed. The most commonly reported symptoms are a fever and a dry cough, leading to shortness of breath. The early symptoms are similar to other common viruses such as the common cold and flu. These illnesses spread more during cold months, but there is no conclusive evidence to suggest that temperature impacts the spread of the SARS-CoV-2 virus. Medical advice should be sought if you are experiencing any of these symptoms.
https://www.usa.gov/government-workshttps://www.usa.gov/government-works
This dataset represents preliminary estimates of cumulative U.S. COVID-19 disease burden for the 2024-2025 period, including illnesses, outpatient visits, hospitalizations, and deaths. The weekly COVID-19-associated burden estimates are preliminary and based on continuously collected surveillance data from patients hospitalized with laboratory-confirmed severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infections. The data come from the Coronavirus Disease 2019 (COVID-19)-Associated Hospitalization Surveillance Network (COVID-NET), a surveillance platform that captures data from hospitals that serve about 10% of the U.S. population. Each week CDC estimates a range (i.e., lower estimate and an upper estimate) of COVID-19 -associated burden that have occurred since October 1, 2024.
Note: Data are preliminary and subject to change as more data become available. Rates for recent COVID-19-associated hospital admissions are subject to reporting delays; as new data are received each week, previous rates are updated accordingly.
References
Among the ten major virus outbreaks in the last 50 years, Marburg ranked first in terms of the fatality rate with 80 percent. In comparison, the recent novel coronavirus, originating from the Chinese city of Wuhan, had an estimated fatality rate of 2.2 percent as of January 31, 2020.
Alarming COVID-19 fatality rate in Mexico More than 812,000 people worldwide had died from COVID-19 as of August 24, 2020. Three of the most populous countries in the world have reported particularly large numbers of coronavirus-related deaths: Mexico, Brazil, and the United States. Out of those three nations, Mexico has the highest COVID-19 death rate, with around one in ten confirmed cases resulting in death. The high fatality rate in Mexico indicates that cases may be much higher than reported because testing capacity has been severely stretched.
Post-lockdown complacency a real danger In March 2020, each infected person was estimated to transmit the COVID-19 virus to between 1.5 and 3.5 other people, which was a higher infection rate than the seasonal flu. The coronavirus is primarily spread through respiratory droplets, and transmission commonly occurs when people are in close contact. As lockdowns ease around the world, people are being urged not to become complacent; continue to wear face coverings and practice social distancing, which can help to prevent further infections.
Over 12 million people in the United States died from all causes between the beginning of January 2020 and August 21, 2023. Over 1.1 million of those deaths were with confirmed or presumed COVID-19.
Vaccine rollout in the United States Finding a safe and effective COVID-19 vaccine was an urgent health priority since the very start of the pandemic. In the United States, the first two vaccines were authorized and recommended for use in December 2020. One has been developed by Massachusetts-based biotech company Moderna, and the number of Moderna COVID-19 vaccines administered in the U.S. was over 250 million. Moderna has also said that its vaccine is effective against the coronavirus variants first identified in the UK and South Africa.